• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Corbus Pharmaceuticals Holdings Inc.

    5/31/24 4:39:16 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRBP alert in real time by email
    S-8 1 crbp_s8_2024_05_31.htm S-8 S-8

    As filed with the Securities and Exchange Commission on May 31, 2024

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    CORBUS PHARMACEUTICALS HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

    Delaware

    46-4348039

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    500 River Ridge Drive

    Norwood, MA 02062

    Telephone: 617-963-0100

    (Address of Principal Executive Offices) (Zip Code)

    CORBUS PHARMACEUTICALS HOLDINGS, INC. 2024 EQUITY COMPENSATION PLAN

    (Full title of the plan)

    Yuval Cohen

    Chief Executive Officer

    Corbus Pharmaceuticals Holdings, Inc.

    500 River Ridge Drive

    Norwood, MA 02062

    Telephone: 617-963-0100

    (Name and address of agent for service)

    Telephone Number, Including Area Code of agent for service)

    Copies to:

    Michael J. Lerner, Esq.

    Steven M. Skolnick

    Lowenstein Sandler LLP

    1251 Avenue of the Americas

    New York, New York 10020

    Telephone: (212) 262-6700

     

     


    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    TABLE OF CONTENTS

    INTRODUCTION

    1

    PART I INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    1

    PART II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    1

    Item 3. Incorporation of Documents by Reference.

    1

    Item 4. Description of Securities.

    2

    Item 5. Interests of Named Experts and Counsel.

    2

    Item 6. Indemnification of Directors and Officers.

    2

    Item 7. Exemption from Registration Claimed.

    2

    Item 8. Exhibits.

    2

    Item 9. Undertakings.

    4

    SIGNATURES

    5

     

     


     

    INTRODUCTION

    This Registration Statement on Form S-8 (this “Registration Statement”) is filed by Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), to register 2,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), newly reserved for issuance under the Corbus Pharmaceuticals Holdings, Inc. 2024 Equity Compensation Plan (the “Plan”), which was approved by the Company’s Board of Directors on March 14, 2024 and by its stockholders on May 16, 2024.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The document(s) containing the information specified in Part I will be sent or given to participants as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not being filed with the Securities and Exchange Commission (the “SEC”) either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents, which have been filed by the Company with the SEC, are hereby incorporated by reference in this Registration Statement:

    •

    The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 12, 2024, as amended by the Company’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2023, filed with the SEC on March 20, 2024;

    •

    The Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024, filed with the SEC on May 7, 2024;

    •

    The Company’s Current Reports on Form 8-K filed with the SEC on January 9, 2024, January 26, 2024, January 29, 2024, January 31, 2024, February 1, 2024 (as amended on February 2, 2024), February 6, 2024, March 20, 2024, April 10, 2024, May 9, 2024 and May 20, 2024 (other than any portions thereof deemed furnished and not filed);

    •

    The Company’s Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 2, 2024, as supplemented by the additional definitive proxy solicitation materials filed with the SEC on April 10, 2024; and

    •

    The description of our common stock, par value $0.0001 per share, contained in our Form 8-A filed on April 14, 2015, including any amendment or report filed for the purpose of updating such description, including the Description of Capital Stock filed as Exhibit 4.10 to our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 7, 2023.

     

    1


     

    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. Copies of these documents are not required to be filed with this Registration Statement, and nothing in this Registration Statement shall be deemed to incorporate information furnished but not filed with the SEC.

    Item 4. Description of Securities.

    Not Applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not Applicable.

    Item 6. Indemnification of Directors and Officers.

    The DGCL authorizes corporations to limit or eliminate, subject to certain conditions, the personal liability of directors to corporations and their stockholders for monetary damages for breach of their fiduciary duties. The Company’s certificate of incorporation limits the liability of the Company’s directors to the fullest extent permitted by Delaware law. In addition, the Company has entered into indemnification agreements with certain of its directors and officers whereby the Company has agreed to indemnify those directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of the Company, provided that such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interests of the Company.

    The Company has director and officer liability insurance to cover liabilities its directors and officers may incur in connection with their services to the Company, including matters arising under the Securities Act. The Company’s certificate of incorporation and bylaws also provide that it will indemnify its directors and officers who, by reason of the fact that he or she is one of the officers or directors of the Company, is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative related to their board role with the Company.

    Item 7. Exemption from Registration Claimed.

    Not Applicable.

    Item 8. Exhibits.

    For a list of exhibits, see the Exhibit Index in this Registration Statement, which is incorporated into this Item by reference.


     

     

    2


     

    EXHIBIT INDEX

    Exhibit

    Number

    Description of Exhibit

    4.1

    Amended and Restated Certificate of Incorporation of the Company, as amended (incorporated by reference to Exhibit 3.1 of the Company’s Annual Report on Form 10-K filed with the SEC on March 7, 2023).

    4.2

    Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 of the Company’s Annual Report on Form 10-K filed with the SEC on March 7, 2023).

    4.3

    Specimen Common Stock Certificate, $0.0001 par value (incorporated herein by reference to Exhibit 4.1 of the Company’s Registration Statement on Form S-3 filed with the SEC on November 10, 2015).

    4.4

    Corbus Pharmaceuticals Holdings, Inc. 2024 Equity Compensation Plan.*

     

    4.5

    Form of Incentive Stock Option Grant Agreement (incorporated herein by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the SEC on May 20, 2024).

    4.6

    Form of Non-Statutory Stock Option Grant Agreement (incorporated herein by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K filed with the SEC on May 20, 2024).

    4.7

    Form of Restricted Stock Award Agreement (incorporated herein by reference to Exhibit 10.4 of the Company’s Current Report on Form 8-K filed with the SEC on May 20, 2024).

    4.8

    Form of Restricted Stock Unit Award Agreement (incorporated herein by reference to Exhibit 10.5 of the Company’s Current Report on Form 8-K filed with the SEC on May 20, 2024).

    5.1

    Opinion of Lowenstein Sandler LLP.*

     

    23.1

    Consent of EisnerAmper LLP.*

    23.2

    Consent of Lowenstein Sandler LLP (filed as part of Exhibit 5.1).*

    24.1

    Power of Attorney (included on the signature page to this registration statement on Form S-8).*

    107

    Calculation of Filing Fee Table.*

     

    *

    Filed herewith.


     

     

    3


     

    Item 9. Undertakings.

    (a) The undersigned Registrant hereby undertakes:

    (1) to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i)

    To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

    (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

    (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

    Provided, however, that Paragraphs (a)(1)(i) and (a)(1)(ii) of this section shall not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.

    (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof:

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.


     

     

    4


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Norwood, Commonwealth of Massachusetts, on this 31st day of May, 2024.

    Corbus Pharmaceuticals Holdings, Inc.

    By:

    /s/ Yuval Cohen

    Yuval Cohen Ph.D.

    Chief Executive Officer

     

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Yuval Cohen Ph.D. and Sean Moran, and each of them, his attorney-in-fact, with full power of substitution for him in any and all capacities, to sign any amendments to this Registration Statement, including any and all pre-effective and post-effective amendments and to file such amendments thereto, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact, or their substitute or substitutes, may do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

    5


     

    Person

    Capacity

    Date

    /s/ Yuval Cohen

    Chief Executive Officer and Director

    May 31, 2024

    Yuval Cohen

    (Principal Executive Officer)

    /s/ Sean Moran

    Chief Financial Officer

    May 31, 2024

    Sean Moran

    (Principal Financial and Accounting Officer)

    /s/ Alan Holmer

    Director

    May 31, 2024

    Alan Holmer

    /s/ Anne Altmeyer

    Director

    May 31, 2024

    Anne Altmeyer

    /s/ Avery Catlin

    Director

    May 31, 2024

    Avery Catlin

    /s/ Rachelle Jacques

    Director

    May 31, 2024

    Rachelle Jacques

    /s/ John Jenkins

    Director

    May 31, 2024

    John Jenkins

    /s/ Peter Salzmann

    Director

    May 31, 2024

    Peter Salzmann

    /s/ Yong Ben

    Director

    May 31, 2024

    Yong Ben

    6


    Get the next $CRBP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRBP

    DatePrice TargetRatingAnalyst
    7/30/2025$28.00Buy
    B. Riley Securities
    2/28/2025Outperform
    William Blair
    12/2/2024Overweight
    Piper Sandler
    7/30/2024$85.00Outperform
    Wedbush
    7/22/2024$80.00Buy
    H.C. Wainwright
    6/26/2024$85.00Buy
    B. Riley Securities
    6/3/2024$60.00 → $80.00Outperform
    Oppenheimer
    5/13/2024$77.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $CRBP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

    NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference, to be held virtually February 25-25, 2026. 36th Annual Oppenheimer Healthcare Life Sciences Conference Format: Virtual presentation and one-on-one investor meetings Date: February 25, 2026 Presentation Time: 3:20pm Eastern TimeWebcast Link: Click Here About CorbusCorbus Pharmaceuticals Holdings, Inc. is a clinical stage oncolog

    2/12/26 8:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

    NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026, in San Francisco, CA. 44th Annual J.P. Morgan Healthcare Conference Format: Presentation and one-on-one investor meetings Date: January 15, 2026 Presentation Time 8:15 a.m. PST/11:15am ESTWebcast Link: Click Here About CorbusCorbus Pharmaceuticals Holdings, Inc. is a clinical stage oncology and obesity company with a diversified portfolio

    1/5/26 7:30:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

    CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of people with obesity (n=12)A 12-week dose-finding study in people with obesity initiated with completion expected in summer 2026Company to host conference call and live webcast today at 8:00 am ET NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the single ascending dose (SAD) and multiple ascending d

    12/11/25 7:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cormorant Asset Management, Lp bought $7,003,761 worth of shares (350,000 units at $20.01) (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    9/24/24 4:04:18 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cormorant Asset Management, Lp bought $23,327,560 worth of shares (550,000 units at $42.41) (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    3/11/24 5:34:06 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cormorant Asset Management, Lp bought $14,250,000 worth of shares (750,000 units at $19.00) (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/6/24 4:00:46 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Smethurst Dominic sold $26,575 worth of shares (3,285 units at $8.09), decreasing direct ownership by 3% to 95,887 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/4/26 4:25:42 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Hodgson Ian sold $19,537 worth of shares (2,415 units at $8.09), decreasing direct ownership by 4% to 51,927 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/4/26 4:24:39 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Hodgson Ian was granted 28,365 shares, increasing direct ownership by 109% to 54,342 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    1/16/26 4:30:03 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities resumed coverage on Corbus Pharma with a new price target

    B. Riley Securities resumed coverage of Corbus Pharma with a rating of Buy and set a new price target of $28.00

    7/30/25 8:22:15 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Corbus Pharma

    William Blair initiated coverage of Corbus Pharma with a rating of Outperform

    2/28/25 7:22:12 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Corbus Pharma

    Piper Sandler initiated coverage of Corbus Pharma with a rating of Overweight

    12/2/24 9:55:40 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SCHEDULE 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    2/10/26 1:14:49 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    1/12/26 7:26:40 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Corbus Pharmaceuticals Holdings Inc.

    8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    12/18/25 4:05:25 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    Leadership Updates

    Live Leadership Updates

    View All

    Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

    NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

    5/19/25 8:00:00 AM ET
    $AKTX
    $CRBP
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

    NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the Corbus Board of Directors. "We are delighted to welcome someone of Winston's stature and expertise to our Board and we look forward to his insights and guidance." "Winston brings an e

    8/20/24 8:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

    NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company's Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company's investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company's h

    2/28/24 8:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    Financials

    Live finance-specific insights

    View All

    Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

    CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of people with obesity (n=12)A 12-week dose-finding study in people with obesity initiated with completion expected in summer 2026Company to host conference call and live webcast today at 8:00 am ET NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the single ascending dose (SAD) and multiple ascending d

    12/11/25 7:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

    NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical stage company focused on oncology and obesity, announced the Company's plan to release results of its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913 prior to the market open on Thursday, December 11, 2025. Corbus will host a conference call and live webcast the same day at 8:00 am ET to review and discuss the Phase 1a data. To register for the webcast, click here . A replay will be available on the Corbus website. About CRB-913CRB-913 is an oral small molecule inverse agonist of the G-protein Coupled Receptor (GPCR) cannabinoid type-1 (

    12/10/25 4:01:00 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 7:48:14 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 6:41:20 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 4:05:29 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care